Public Sector Pension Investment Board Has $18.24 Million Holdings in Glaukos Corporation $GKOS

Public Sector Pension Investment Board increased its position in shares of Glaukos Corporation (NYSE:GKOS) by 14.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 223,708 shares of the medical instruments supplier’s stock after buying an additional 28,866 shares during the period. Public Sector Pension Investment Board’s holdings in Glaukos were worth $18,243,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UMB Bank n.a. grew its holdings in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 158 shares during the period. REAP Financial Group LLC bought a new stake in shares of Glaukos during the 3rd quarter valued at about $40,000. AlphaQuest LLC grew its stake in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the period. SBI Securities Co. Ltd. increased its holdings in Glaukos by 42.9% in the third quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 362 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Stock Performance

GKOS opened at $109.51 on Friday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78. The company has a market cap of $6.29 billion, a price-to-earnings ratio of -71.11 and a beta of 0.70. The company’s fifty day moving average price is $114.64 and its two-hundred day moving average price is $98.00. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GKOS. William Blair raised shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. BTIG Research raised their price target on shares of Glaukos from $123.00 to $131.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $125.00 price target on shares of Glaukos in a research note on Wednesday, January 14th. Wells Fargo & Company upped their price objective on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Finally, JPMorgan Chase & Co. raised their target price on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average price target of $132.54.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of Glaukos stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the completion of the transaction, the chief financial officer owned 50,488 shares in the company, valued at approximately $5,301,240. The trade was a 0.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the sale, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 329,655 shares of company stock worth $37,752,234 in the last 90 days. Company insiders own 5.80% of the company’s stock.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.